Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Akoya Biosciences

Akoya Biosciences (NASDAQ: AKYA) focuses on spatial biology within the biotechnology industry. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya primarily serves the needs of researchers across discovery, translational, and clinical research sectors. It was founded in 2015 and is based in Menlo Park, California.

Headquarters Location

100 Campus Drive 6th Floor

Menlo Park, California, 01762,

United States




Expert Collections containing Akoya Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akoya Biosciences is included in 2 Expert Collections, including Digital Health.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Oncology Tech

457 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

Akoya Biosciences Patents

Akoya Biosciences has filed 17 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • analytical chemistry
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, Immune system, Immunology, Clusters of differentiation


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, Immune system, Immunology, Clusters of differentiation



Latest Akoya Biosciences News

The Growing demand for Spatial OMICS in Cancer Research is Driving the Global Spatial OMICS Market.

Nov 30, 2023

News Provided By Share This Article Global Spatial OMICS Market to Reach USD 566.1 Mn by 2031, with Rising CAGR of 11.2% by 2031: The Niche Research WILMINGTON, DELAWARE, UNITED STATES, November 30, 2023 / / -- Spatial OMICS refers to a cutting-edge field in biology and biotechnology that focuses on analyzing molecular information within the context of spatial organization in tissues and cells. This field combines techniques from genomics, transcriptomics, proteomics, and other "omics" disciplines with spatial information to provide a more comprehensive understanding of cellular and tissue function. This technique allows researchers to simultaneously analyze gene expression within specific regions of tissue. It involves spatially capturing RNA molecules and sequencing them, revealing the gene expression patterns within the context of tissue architecture. Trends in the Global Spatial OMICS Market Spatial OMICS is particularly relevant in cancer research, where tumor heterogeneity and interactions with the microenvironment play a crucial role. The ability to analyze gene expression and protein distribution in relation to tumor architecture is enhancing the understanding of cancer progression. Researchers are gaining new understanding of cancer in its original physical setting because of spatial OMICS capacity to maintain the architecture of tissue from patient samples. Spatial OMICS, when combined with data from other modalities such as imaging, genes, and proteomics, gives a comprehensive, multimodal knowledge of disease causes. For these reasons, spatial OMICS is set to deliver significant advances in cancer research in the next years. Furthermore, spatial OMICS technology allows for the visualisation of previously unobservable cell architecture and biological activities, which may be utilised to create molecular-level "cell atlases" of various species. Spatial OMICS has the potential to contribute in treatment development, cancer characterisation, and infectious disease research. The market for spatial OMICS solutions is expanding, but technological hurdles such as data gathering, processing, storage, and standardised reporting must be overcome before the sector can reach its full potential. With its potential to transform knowledge of biological systems in the long run the global spatial OMICS market will continue to grow during the forecast period. Key Takeaways from the Global Spatial OMICS Market • Spatial transcriptomics had a significant share in the global spatial OMICS market in 2022. Many spatial transcriptomics techniques offer single-cell resolution, which is enabling researchers to study gene expression at an individual cell level within their spatial context. This level of granularity is crucial for identifying distinct cell types, characterizing cell states, and uncovering cellular heterogeneity within tissues. Moreover, due to the rising interest, researchers are adopting spatial transcriptomics reflecting its potential to enhance understanding of complex biological systems, disease processes, and tissue-specific gene expression dynamics. As the field continues to evolve and mature, spatial transcriptomics is expected to play a pivotal role in the global spatial OMICS market. • Spatial OMICS techniques are being used by a wide range of researchers, institutions, and industries for various applications across the fields of biology, medicine, and biotechnology. In 2022, Academic and Research Institutions end user segment had the highest share in the spatial OMICS market in 2022. The use of spatial OMICS to translate real-time tissue reactions to an external agent expands the technology's use in translational research. They apply spatial OMICS to obtain a better knowledge of complicated biological systems, discover new insights, and improve fundamental scientific concepts. • During the forecast period, Asia Pacific region is anticipated to be the fastest growing region in the spatial OMICS market. The biotechnology industry in Asia has been expanding rapidly, with a focus on drug discovery, precision medicine, and diagnostics, along with strong research programs in genomics, proteomics, and related fields. Countries such as China, Japan, South Korea, and Singapore made significant investments in life sciences and biotechnology, fostering an environment conducive to the development and adoption of cutting-edge technologies like spatial OMICS. Besides due to the rising relevance of cancer in Asia there is a strong interest in advancing cancer research and diagnostics wherein spatial OMICS techniques play a vital role in understanding tumor heterogeneity and optimizing treatment strategies. Thus, considering the above factors the spatial OMICS market has huge scope for the growth in the upcoming years. The competitive landscape of the global spatial OMICS market is characterized by a mix of established companies, startups, and academic research institutions driving innovation in the field. Many academic research groups and institutions are actively involved in developing spatial OMICS technologies, often collaborating with industry partners. Several collaborative initiatives, both public and private, are fostering innovation in spatial OMICS. These may involve partnerships between academia, industry, and government organizations strengthening the growth of the global spatial OMICS market. Key Developments in the Global Spatial OMICS Market In June 2022, Akoya Biosciences, Inc. presented data created using its proprietary RNA chemistry, which allows whole-slide spatial multiomics at single-cell resolution on the PhenoCycler-Fusion system. This unique spatial transcriptomics solution will be added to Akoya's industry-leading spatial proteomics offering on the PhenoCycler-Fusion, giving customers a strong option for whole-slide spatial multiomics. In October 2022, NanoString technology, Inc. established a partnership with Visiopharm to speed the development of new biomarkers and therapeutic targets by leveraging cutting-edge spatial imaging and machine learning technology. Key players operating in the global spatial OMICS market are o 10x Genomics o Pharmaceutical and Biotechnology Companies o Contract Research Organizations (CROs) o Others o North America (U.S., Canada, Mexico, Rest of North America) o Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe) o Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific) o Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) o Latin America (Brazil, Argentina, Rest of Latin America) Consult with Our Expert:

Akoya Biosciences Frequently Asked Questions (FAQ)

  • When was Akoya Biosciences founded?

    Akoya Biosciences was founded in 2015.

  • Where is Akoya Biosciences's headquarters?

    Akoya Biosciences's headquarters is located at 100 Campus Drive, Menlo Park.

  • What is Akoya Biosciences's latest funding round?

    Akoya Biosciences's latest funding round is IPO.

  • How much did Akoya Biosciences raise?

    Akoya Biosciences raised a total of $87M.

  • Who are the investors of Akoya Biosciences?

    Investors of Akoya Biosciences include Paycheck Protection Program, Telegraph Hill Partners, Agilent Technologies, Innovatus Capital Partners, Piper Jaffray Merchant Banking and 3 more.

  • Who are Akoya Biosciences's competitors?

    Competitors of Akoya Biosciences include Cell Microsystems, Lunaphore Technologies, NanoImaging Services, PictorLabs, 10X Genomics and 7 more.


Compare Akoya Biosciences to Competitors

Algorithmic Biologics

Algorithmic Biologic offers molecular discovery and diagnostics solutions. Its first product, Tapestry, is a regulatory-approved, algorithmic solution to provide large-scale COVID-19 testing. The company was founded in 2021 and is based in Bangalore, India.

Singleron Biotechnologies Logo
Singleron Biotechnologies

Singleron Biotechnologies is a biotech company. The company focuses on applying single-cell analysis technologies in the healthcare sector. The company offers a comprehensive solution for single-cell multi-omics sequencing, which allows for novel approaches in clinical research and molecular diagnostics. The company primarily serves the healthcare industry, particularly in areas of clinical diagnosis, drug development, and health management. It was founded in 2018 and is based in Cologne, Germany.

Basepair Logo

Basepair is a bioinformatics company operating in the healthcare and technology sectors. The company provides a next-generation data analysis platform for Next-Generation Sequencing (NGS), offering services such as RNA-Seq Analysis, ChIP-Seq Analysis, DNA-Seq Analysis, and ATAC-Seq Analysis. Basepair primarily serves academic researchers, clinical laboratories, library prep kit manufacturers, R&D teams, and sequencing service providers. It was founded in 2015 and is based in New York, New York.


CloudSeq provides cloud-based bioinformatics solutions. It offers myClinGen a digital healthcare solution to provide personalized treatment based on objective data science-driven automated workflows on a supercomputer and myAgriGen a big data analytics solution for plant geneticists and plant breeders to practice molecular breeding and genome editing with automated workflows hosted on a supercomputer. It was founded in 2014 and is based in Singapore, Singapore.

LighTopTech Logo

LighTopTech's new standard in rapid nondestructive high-resolution imaging uses a proprietary biomimetic microscope design with liquid lens technology. This lens dynamically refocuses at different depths inside the sample to nondestructively obtain high-resolution volumetric images of materials.

TRIBVN Healthcare Logo
TRIBVN Healthcare

TRIBVN Healthcare is a company focused on the digital transformation of cancer diagnosis within the healthcare sector. The company offers innovative solutions for the management, analysis, and sharing of cellular images, leveraging artificial intelligence technologies to support diagnostic decision-making and scientific evaluation. Its primary customers include diagnostic laboratories, pharmaceutical companies, and biotech organizations. It was founded in 2011 and is based in Paris, France.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.